drugset / Trial / NCT06942624
Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection
Phase 1/2
Not yet recruiting
1 enrolled
Orthopaedic Innovation Centre
Cytophage Technologies Inc. · collabOttawa Hospital Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of a bacteriophage therapy in a patient with a methicillin-susceptible Enterococcus faecium (E. faecium) prosthetic joint infection (PJI) of the hip. We have exhausted all surgical and medical management of PJI for our patient. The phage will be administered to the study patient during a 14 days period via intravenous and intra-articular. The patient will be monitored in clinic for up to 1 year.
Timeline
- Start
- 2025-05
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIP-200 | Other / unclassified | — | Intravenous |